Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAA817 vs Standard of Care in PSMA-positive mCRPC (PSMAcTION)
NCT06780670Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Feb 2025
- Primary completion
- Jun 2028
- Modality
- Alpha Emitters, Beta Emitters, Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of actinium-225 PSMA-617 in prostate cancer (PCa) (4 arms), sponsored by Novartis. Primary endpoints: Biochemical response rate at 24 months, Adverse Events, Serious Adverse Events, and deaths and 3 more. Started Feb 2025; status: recruiting.
02
Drugs
actinium-225 PSMA-617
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06780670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780670.